美国住院成人中呼吸道合胞病毒与COVID-19及流感疾病的严重程度比较
这项前瞻性队列研究纳入2022年2月1日至2023年5月31日美国20个州25家医院的7998例因急性呼吸道疾病住院且实验室确诊RSV、SARS-CoV-2或流感的成人。RSV患者IMV或死亡发生率为12.0%,未接种疫苗COVID-19患者为14.1%、已接种疫苗COVID-19患者为9.2%,未接种疫苗流感患者为10.3%、已接种疫苗流感患者为5.1%。校正分析显示,RSV患者IMV或死亡风险与未接种疫苗COVID-19(aOR 0.82,P=0.22)或流感(aOR 1.20,P=0.35)无显著差异,但显著高于已接种疫苗COVID-19(aOR 1.38,P=0.03)或流感(aOR 2.81,P<0.001)患者。研究提示,在首批RSV疫苗推荐前,RSV疾病较不常见但严重程度与未接种疫苗的COVID-19或流感相当,且高于已接种疫苗者。
要点
- RSV住院成人IMV或死亡发生率为12.0%(58例),未接种疫苗COVID-19为14.1%(201/1422),已接种疫苗COVID-19为9.2%(458/5000)。
- 未接种疫苗流感患者IMV或死亡为10.3%(72/699),已接种疫苗流感患者为5.1%(20/393)。
- 校正后RSV与未接种疫苗COVID-19的IMV或死亡风险无显著差异(aOR 0.82,95%CI 0.59-1.13,P=0.22)。
- 校正后RSV与未接种疫苗流感的IMV或死亡风险无显著差异(aOR 1.20,95%CI 0.82-1.76,P=0.35)。
- 校正后RSV患者IMV或死亡风险显著高于已接种疫苗COVID-19(aOR 1.38,95%CI 1.02-1.86,P=0.03)和已接种疫苗流感(aOR 2.81,95%CI 1.62-4.86,P<0.001)。
适用人群与场景
- 2022年2月1日至2023年5月31日在美国20个州25家医院住院的18岁及以上成人,因急性呼吸道疾病住院且实验室确诊RSV、SARS-CoV-2或流感感染。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入25家美国医院、7998例成人(中位年龄67岁,IQR 54-78岁;女性4047例,50.6%)。
- RSV住院484例(6.1%),COVID-19住院6422例(80.3%),流感住院1092例(13.7%)。
- RSV患者IMV或死亡58例(12.0%);未接种疫苗COVID-19患者201/1422例(14.1%),已接种疫苗COVID-19患者458/5000例(9.2%);未接种疫苗流感患者72/699例(10.3%),已接种疫苗流感患者20/393例(5.1%)。
- 校正后RSV与未接种疫苗COVID-19的IMV或死亡风险无显著差异(aOR 0.82,95%CI 0.59-1.13,P=0.22)。
- 校正后RSV与未接种疫苗流感的IMV或死亡风险无显著差异(aOR 1.20,95%CI 0.82-1.76,P=0.35)。
- 校正后RSV患者IMV或死亡风险显著高于已接种疫苗COVID-19患者(aOR 1.38,95%CI 1.02-1.86,P=0.03)。
- 校正后RSV患者IMV或死亡风险显著高于已接种疫苗流感患者(aOR 2.81,95%CI 1.62-4.86,P<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,了解成人RSV疾病的严重程度有助于指导2023年6月21日美国疾病控制与预防中心基于共同临床决策对60岁及以上成人推荐首批RSV疫苗的临床决策。
- 在本队列中,RSV住院成人发生IMV或死亡的风险与未接种疫苗的COVID-19或流感住院成人相似,但高于已接种疫苗的COVID-19或流感住院成人。
指南或共识出处
- 美国疾病控制与预防中心(CDC)于2023年6月21日基于共同临床决策推荐首批RSV疫苗用于60岁及以上成人。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical decision-making. Understanding the severity of RSV disease in adults can help guide this clinical decision-making.
OBJECTIVE: To describe disease severity among adults hospitalized with RSV and compare it with the severity of COVID-19 and influenza disease by vaccination status.
DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, adults aged 18 years and older admitted to the hospital with acute respiratory illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20 US states from February 1, 2022, to May 31, 2023. Clinical data during each patient's hospitalization were collected using standardized forms. Data were analyzed from August to October 2023.
EXPOSURES: RSV, SARS-CoV-2, or influenza infection.
MAIN OUTCOMES AND MEASURES: Using multivariable logistic regression, severity of RSV disease was compared with COVID-19 and influenza severity, by COVID-19 and influenza vaccination status, for a range of clinical outcomes, including the composite of invasive mechanical ventilation (IMV) and in-hospital death.
RESULTS: Of 7998 adults (median [IQR] age, 67 [54-78] years; 4047 [50.6%] female) included, 484 (6.1%) were hospitalized with RSV, 6422 (80.3%) were hospitalized with COVID-19, and 1092 (13.7%) were hospitalized with influenza. Among patients with RSV, 58 (12.0%) experienced IMV or death, compared with 201 of 1422 unvaccinated patients with COVID-19 (14.1%) and 458 of 5000 vaccinated patients with COVID-19 (9.2%), as well as 72 of 699 unvaccinated patients with influenza (10.3%) and 20 of 393 vaccinated patients with influenza (5.1%). In adjusted analyses, the odds of IMV or in-hospital death were not significantly different among patients hospitalized with RSV and unvaccinated patients hospitalized with COVID-19 (adjusted odds ratio [aOR], 0.82; 95% CI, 0.59-1.13; P = .22) or influenza (aOR, 1.20; 95% CI, 0.82-1.76; P = .35); however, the odds of IMV or death were significantly higher among patients hospitalized with RSV compared with vaccinated patients hospitalized with COVID-19 (aOR, 1.38; 95% CI, 1.02-1.86; P = .03) or influenza disease (aOR, 2.81; 95% CI, 1.62-4.86; P < .001).
CONCLUSIONS AND RELEVANCE: Among adults hospitalized in this US cohort during the 16 months before the first RSV vaccine recommendations, RSV disease was less common but similar in severity compared with COVID-19 or influenza disease among unvaccinated patients and more severe than COVID-19 or influenza disease among vaccinated patients for the most serious outcomes of IMV or death.
参考来源
- Surie D, Yuengling KA, DeCuir J, et al. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024. PMID: 38573635. doi:10.1001/jamanetworkopen.2024.4954
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。